AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03770559 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open RAMPS
Description: Eligible patients diagnosed as left-side pancreatic cancer in Open-RAMPS group will be treated by open invasive RAMPS surgery
Study NCT01339741 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D3
Description: Vitamin D3, oral supplement, 12 weeks
Study NCT01339741 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo, oral route, 12 weeks
Study NCT03458286 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BRH-A2 wound healing device
Description: Combined ultrasound and electric current stimulation (CUSECS) is a combination therapy provided by the BRH-A2 wound healing device. This study is testing the effectiveness of the treatment CUSECS. The electric current stimulation is provided by attaching small electrodes around the ulcers. A probe is used on the ulcers to provide the ultrasound waves. Both aiming to increase the blood flow to an area to increase wound healing.
Study NCT02643836 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: PEMF
Description: The PEMF device (Rio Grande Neurosciences - RGN) the investigators would be testing has been shown to have significant anti-inflammatory effects in animals and humans and an excellent safety profile in several clinical studies. Key findings demonstrated that PEMF-treated rodents with a closed-head TBI exhibited a 5-fold decrease in IL-1b in the cerebral spinal fluid, an outcome associated with decreased neuropathology and improved function.
Study NCT02643836 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEMF
Description: The PEMF device (Rio Grande Neurosciences - RGN) the investigators would be testing has been shown to have significant anti-inflammatory effects in animals and humans and an excellent safety profile in several clinical studies. Key findings demonstrated that PEMF-treated rodents with a closed-head TBI exhibited a 5-fold decrease in IL-1b in the cerebral spinal fluid, an outcome associated with decreased neuropathology and improved function.
Study NCT02687425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone
Description: 15mg/day,po
Study NCT02687425 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: imatinib mesylate
Description: 400mg/day,po
Study NCT01975428 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DM Pgm + device
Description: Disease management program plus a device corresponding to an individual's disease(s):~iBGStar - iPhone enabled capillary blood glucose meter. Subjects test blood glucose up to 4 times per day, every day.~Withings BP monitor - iPhone enabled home blood pressure monitor. Subjects test their blood pressure 2 times per day, up to 3 days per week.~iPhone enabled Alive Cor ECG monitor. Participants take an ECG reading only when symptomatic.
Study NCT01975428 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control
Description: All study participants, including participants randomized to the control arm, were enrolled in the HealthComp disease management program, which involved outreach by HealthComp nursing staff for purposes of relaying medical education and wellness information with regard to disease prevention and chronic disease management.
Study NCT03082703 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Text Messaging
Description: Subjects contacted 3 times weekly via text messaging for the study period.
Study NCT01644344 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No-Xray
Description: Treatment group: these patients will not have routine post-operative in hospital radiographs, or radiographs in clinic at two weeks. After examining the patient, the surgeon or resident can order radiographs if required at any time. The decision will be made based on patient complaints of increased pain, appearance of abuse of the splint or cast suggesting lack of compliance or visible clinical deformity of the limb. The reason leading to radiographs will be documented by the ordering physician. If radiographs are ordered based on a wound complication, this will be specifically documented. Radiographic findings will be documented on a form identical to that used for the control group.
Study NCT01644344 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Xray
Study NCT01394471 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intranasal Oxytocin Spray
Description: 6 insufflations (24IU of oxytocin total) given twice daily for 12 weeks
Study NCT01394471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intranasal Oxytocin Spray
Description: 6 insufflations (24IU of oxytocin total) given twice daily for 12 weeks
Study NCT03118349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MVT-1075
Description: MVT-1075 administered in two fractions, with each administration of MVT-1075 preceded by blocking dose of MVT-5873.
Study NCT03118349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MVT-5873
Description: MVT-5873 administered intravenously as a non-radioactive blocking agent prior to administration of MVT-1075.
Study NCT03988322 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-dose CT screening with quantitative assessment and management of imaging biomarkers
Description: Participants will be screened with a low-dose CT (a Philips 256-slice CT system). The CT images will be obtain according to the pre-defined CT scan protocol. This CT protocol is developed for quantitative assessment of lung nodules, COPD and coronary artery calcium. Detected lung nodules will be managed according to the European volume-based protocol, based on the volume and volume doubling time of lung nodule. COPD will be management according to the result of lung function test. The imaging biomarkers (eg., emphysema index, airway wall thickness, and coronary artery calcium ) will be quantitatively registered. In addition, a number of participants' characteristics will be collected: physical examination (weight, height, blood pressure), laboratory measurements (eg., fasting plasma glucose, total cholesterol, HDL-cholesterol). The social-demographic characteristics, risk factors of the 3 diseases, and health status of the participants will be collected through questionnaires.
Study NCT03988322 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Low-dose CT screening with visual assessment and management of imaging biomarkers
Description: Participants will be screened with a low-dose CT (a Philips 64 MDCT system). The CT images will be obtain according to the routine CT scan protocol for lung cancer screening in the hospital. Detected lung nodules will be managed according to the diameter of the nodule based on the NCCN Clinical Practice Guideline in Oncology for Lung Cancer Screening. Detected emphysema and/or bronchial wall thickness, coronary artery calcium will be qualitatively recorded (yes/no).
Study NCT02743819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab given every 3 weeks (200 mg) by IV infusion.
Study NCT02743819 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab given every 3 weeks (200 mg) by IV infusion for total of 4 doses.
Study NCT02862860 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: blood sample
Study NCT02862860 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood sample
Study NCT02862860 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: urine sample
Study NCT02862860 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: urine sample
Study NCT02862860 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: installation of Holter
Study NCT00288353 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: aripiprazole (Abilify)
Description: active drug given daily as per package insert according to standard clinical care for twelve month duration of study. Subject will be switched from current antipsychotic to this drug or other randomized study medication.
Study NCT00288353 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ziprasidone (Geodon)
Description: active medication will be given daily as per package insert according to standard clinical care for the twelve month duration of the study. Subject will be switched from current antipsychotic medication to this medication or the other randomized medication.
Study NCT02801903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB204 4%
Description: Topically Once Daily (AM)
Study NCT01891435 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral paracetamol
Description: after giving medicine temperature is checked every 30 minutes for 2 hours
Study NCT01891435 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous paracetamol
Description: after giving medicine temperature is checked every 30 minutes for 2 hours
Study NCT01891435 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intramuscular diclofenac
Description: after giving medicine temperature is checked every 30 minutes for 2 hours
Study NCT03783546 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Description: Acupuncture is a complementary therapy in which, hair-thin, sterile disposable needles are inserted into various spots on your skin, with the goal of affecting body's natural healing system
Study NCT03783546 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: the current standard of care with non-hormonal pharmacotherapy of western medicine
Study NCT00647751 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine Tablets 25 mg
Description: 2x25mg, single dose fed
Study NCT00647751 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lamictal® Tablets 25 mg
Description: 2x25mg, single dose fed
Study NCT04158596 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Vibration Therapy
Description: SDX-3101 is used for drug-free treatment of CRSsNP in adults.
Study NCT04158596 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Vibration Therapy
Description: SDX-3101 is used for drug-free treatment of CRSsNP in adults.
Study NCT02642484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gabapentin
Description: Gapapentin twice daily
Study NCT02642484 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Calcium Carbonate
Description: calcium carbonate twice daily
Study NCT03675672 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol Oral Tablet
Description: Misoprostol 200mcg
Study NCT03675672 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo Tablet
Study NCT03159741 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inhibitor + GLP-2
Description: Inhibitor and GLP-2 are used as study tools.
Study NCT03159741 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo + GLP-2
Description: Placebo and GLP-2 are used as study tools.
Study NCT03159741 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo + GIP
Description: Placebo and GIP are used as study tools.
Study NCT03159741 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Saline
Description: Placebo
Study NCT00906919 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Regular diabetes patient education
Description: Professionally-led diabetes patient education delivered by health professionals over a two day period
Study NCT00906919 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Augmented diabetes patient education
Description: Professionally-led diabetes patient education led by nurse and dietitian over a two day period augmented by participation in the Stanford Chronic Disease Self-Management Program. This program takes place for 2 1/2 hours per week for six consecutive weeks.
Study NCT01337804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omeprazole/sodium bicarbonate
Description: Single 20 mg dose of omeprazole/sodium bicarbonate powder for oral suspension
Study NCT01337804 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omeprazole magnesium
Description: Single 40 mg capsule of omeprazole given orally
Study NCT03977662 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Co-transplantation of PTG with pancreatic islets
Description: Co-transplantation of allogeneic parathyroid glands (PTG) with adult pancreatic islets (both PTG and pancreatic islets obtained from same deceased donor) in people with Type 1 diabetes in the intramuscular (IM) site with stable function of liver or kidney allografts on chronic immunosuppression
Study NCT02535663 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: RG
Description: The 100mg Korean citrus Hallabong peel polysaccharide contained 60mg rhamnogalacturonan (RG), 20mg mono- and di-saccharide, 5mg polyphenol, 5mg ash and 10mg moisture
Study NCT02535663 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Same product without RG
Study NCT02211144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIBR 796 BS
Study NCT02211144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02211144 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01301820 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: azacitidine
Description: azacitidine sc 75 mg/m²/d (d1- d7)
Study NCT01301820 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Lenalidomide
Description: lenalidomide 10mg/d (d1- d21)
Study NCT02207270 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Same day discharge
Description: Patients randomized to SDD will be discharged home on the day of their PCI, at least 6 hours following its completion. They will receive a follow up phone call from a study coordinator the next day and at 30 days to ascertain what costs (if any) were accrued and whether any adverse outcomes occurred.
Study NCT02207270 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Overnight Stay
Description: Patients who experienced uncomplicated PCI, as well as an uncomplicated 6-hour observation period, will be randomly assigned to an overnight stay, generally considered standard or routine care. Patients randomized to overnight stay will be discharged the following morning to receive a follow up phone call at 30 days to ascertain what costs (if any) were accrued and whether any adverse outcomes occurred.
Study NCT04071795 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opt-Out Reminder
Description: half will receive a clinical reminder that includes a standing NRT order and a referral to cessation counseling that will automatically generate unless the provider actively opts-out
Study NCT04071795 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Opt-In Reminder
Description: Half of the psychiatrists will receive a reminder that encourages the psychiatrist to offer cessation medications and referral to cessation counseling to patients interested in quitting
Study NCT00931333 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: non percutaneous vertebroplasty
Description: The patient will undergo general anaesthetic. With a low invasive approach, 4 screws will be placed in pedicles of vertebra under and above the fractured vertebra. The reduction of the fracture will be realised by a smooth movement, and screws positions will be verified by a radio control, with a guided navigation system. The stems will be placed and locked. After the screw positioning, the fractured vertebra pedicles will be reached by a low invasive approach, using a 6 mm trocar, to raise, if necessary, the vertebral plate. Then the cement will be injected in the vertebral body, under radio control. When the maximal volume (6 to 8 ml) is reached, or if an extra vertebral leak is detected, the cement injection is stopped. Then the incision is closed. The next day, the patient will be placed in a corset for a 2 months period.
Study NCT00438347 — intervention group
Intervention type: BEHAVIORAL
Intervention: Aerobic Exercise
Description: One hour per day three times a week for one year
Study NCT00438347 — intervention group
Intervention type: BEHAVIORAL
Intervention: Stretching and toning
Description: One hour per day three times a week for one year
Study NCT01387230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719
Description: 62.5 mcg
Study NCT01387230 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK573719
Description: 125mcg
Study NCT01387230 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT05332184 — intervention group
Intervention type: PROCEDURE
Intervention: aortic valve surgery
Study NCT04271787 — intervention group
Intervention type: OTHER
Intervention: questionnaire
Description: Questionnaire
Study NCT01561781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: Oral tablets 0.25mg, single dose
Study NCT01561781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: Oral tablets, 300 mg, single dose
Study NCT03730974 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Protac Ball BlanketTM (7kg Flexible)
Description: All patients will wear a MotionLogger Micro Watch from Ambulatory Monitoring Inc. NY in all four weeks during all 24hours of the day.
Study NCT02174796 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: surgical treatment
Description: patients who chose to undergo a surgical correction (Ravitch or Nuss type intervention).
Study NCT02174796 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: orthopedic treatment
Description: orthopedic treatment by vacuum bell.
Study NCT00505869 — intervention group
Intervention type: BEHAVIORAL
Intervention: Health & Wellness Intervention
Description: Counseling focusing on health concerns related to pregnancy, information about smoking and pregnancy, tips for quitting, and problem-solving skills to manage situations that might be triggers for smoking.
Study NCT00505869 — intervention group
Intervention type: BEHAVIORAL
Intervention: Questionnaire
Description: Questionnaires about mood, confidence in quitting, smoking behavior, and social support.
Study NCT00505869 — intervention group
Intervention type: BEHAVIORAL
Intervention: Mood Management Intervention
Description: Counseling focusing on learning to manage negative moods (depressed mood, tension, anxiety), as well as providing tips for quitting smoking, problem-solving skills, and information about smoking and pregnancy.
Study NCT03370471 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Retrieval Practice + Moderate Intensity Exercise
Description: Subjects will engage in 30 minutes of moderate-intensity cycling prior to word learning using Retrieval Practice (active retrieval during learning)
Study NCT03782246 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT
Description: Cognitive Behavioral Therapy
Study NCT04114760 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: patchy-type wireless ECG
Description: This device consists of a single patchy and save the ECG result as a Potable Document Format. Also can transfer to hospital using wifi-network.
Study NCT04114760 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: defibrillator ECG
Description: This device is essential equipment in ambulance. For 12-lead ECG examination the connector need to replace for specific cable.
Study NCT00686712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 1- Insulin glargine QHS
Description: Insulin glargine at bedtime (dose titrated to maintain 50% of fasting glucose readings \<120 mg/dL)
Study NCT00686712 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2 - Insulin glargine QAM
Description: Insulin glargine in AM (dose titrated to maintain 50% of pre-supper glucose readings \<120 mg/dL)
Study NCT00686712 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 3 - NPH insulin QHS
Description: NPH insulin at bedtime (dose titrated to maintain 50% of fasting glucoses \<120 mg/dL)
Study NCT01973764 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ultrasound guided ventricular drain insertion
Description: Ventricular puncture and insertion of the intraventricular catheter is performed under ultrasound guidance.
Study NCT01973764 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: landmark-based ventricular drain insertion
Description: Ventricular puncture and insertion of the intraventricular catheter is performed without any guiding devices and is based on anatomical landmarks.
Study NCT00949702 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vemurafenib
Description: 960 mg b.i.d. continuous oral dosing
Study NCT00514839 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing
Description: Two sessions of Motivational Interviewing (after baseline assessment and 4 weeks later) plus one individualized feedback based on the Transtheoretical Model of Behavior Change (8 weeks after baseline assessment)
Study NCT00059462 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2 SA
Description: HAART and Bay 50-4798
Study NCT00059462 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HAART
Description: HAART alone
Study NCT04119414 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Spear and Shield (S&S) Program
Description: The S\&S Program is a comprehensive sexual risk reduction intervention consisting of 4 weekly 90-minute manualized group sessions conducted by a trained Community Health Center (CHC) facilitator.